Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More [Yahoo! Finance]
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $54.00 to $55.00. They now have an "outperform" rating on the stock.
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at JMP Securities from $60.00 to $80.00. They now have a "market outperform" rating on the stock.